Results 71 to 80 of about 1,483,959 (183)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2018
JAK2V617F is a gain of function point mutation that occurs in Myeloproliferative Neoplasm (MPN) patients and deranges their hemopoiesis at cellular level. We speculate that hyperfunctioning JAK2 can modify osteoclast (OCL) homeostasis in MPN patients. We
Emmanouil Spanoudakis   +7 more
doaj   +1 more source

Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes

open access: yesEuropean Journal of Pain, Volume 30, Issue 8, September 2026.
ABSTRACT Introduction Erythromelalgia is a rare disorder characterised by burning pain, erythema and increased skin temperature in the extremities. Its pathophysiological heterogeneity, together with variable treatment responses, complicates management in the absence of evidence‐based guidelines.
Camille Racca   +8 more
wiley   +1 more source

Polycythemia vera: Correlation of JAK2V617F mutation with clinicohematologic characteristics. A single centre experience.

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2014
Introduction Janus kinase2 (JAK2) V617F mutation in myeloid cells has been reported from the majority of patients with Polycythemia vera (PV). Materials & Methods A cross sectional study was conducted to review clinical records of 93 cases of ...
Deepti Mutreja   +6 more
doaj  

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

open access: yesJournal of Experimental & Clinical Cancer Research, 2019
Background The JAK2-STAT signaling pathway plays a critical role in myeloproliferative neoplasms (MPN). An activating mutation in JAK2 (V617F) is present in ~ 95% of polycythemia vera, essential thrombocythemia, and primary myelofibrosis cases.
Min Hu   +9 more
doaj   +1 more source

Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis

open access: yesActa Neurologica Scandinavica, 2018
To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation.
O. Zloto   +5 more
semanticscholar   +1 more source

Dissecting Bone Marrow Fibrosis in Philadelphia‐Negative Myeloproliferative Neoplasms: Multiple Roads Lead to Rome

open access: yesHematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Philadelphia‐negative myeloproliferative neoplasms (MPN), a spectrum of blood malignancies characterized by uncontrolled myeloid proliferation, persist as a key challenge in onco‐hematology due to their intricate molecular background, heterogeneous clinical phenotypes, and variable prognoses.
Mariagiovanna Ballato   +8 more
wiley   +1 more source

Incidence of the JAK2V617F Mutation in Chronic Myeloproliferative Disorders

open access: yesJournal of Contemporary Medicine, 2013
Amaç: Orta Karadeniz Bölgesi’nde BCR/ABL negatif kronik miyeloproliferatif hastalık (KMH) tanısıyla takip edilen olguların JAK2V617F mutasyon sıklığı ve bu mutasyonun hastalığın klinik özelliklerine etkisi açısından incelenmesi amaçlanmıştır.
DEMİR, Ayşe Kevser   +5 more
openaire   +2 more sources

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories

open access: yesOncoTarget, 2017
To date, a plenty of techniques for the detection of JAK2V617F is used over different laboratories, with substantial differences in specificity and sensitivity.
M. Perricone   +44 more
semanticscholar   +1 more source

The Germline SH2B3rs111340708 Splicing Variant Drives Intron Retention and Protein Instability by Impacting Clinical Outcomes in Core Binding Factor AML

open access: yesHematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT The SH2B3 gene, also known as LNK, encodes an adaptor protein that negatively regulates key hematopoietic signaling pathways, including JAK–STAT, MAPK, and PI3K/AKT, thereby maintaining hematopoietic homeostasis. SH2B3 interacts with major signaling regulators such as JAK2, MPL, FLT3, and KIT. Loss‐of‐function alterations have been reported in
Marta Rachele Stefanucci   +9 more
wiley   +1 more source

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

open access: yesInternational Journal of Medical Sciences, 2016
Most patients with polycythemia vera (PV) and half of essential thrombocythemia (ET) possess an activating JAK2V617F mutation. The objective of this study was to better define the effect of JAK2V617F mutant allele burden on clinical phenotypes in Chinese
Shixiang Zhao   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy